Table 1. Open in new tab Attributes of...

							Patients with bleeding events, No./Total
Chesebro et al, 1983, US	WFN	500	Valve replacement	NR	28	No	9/183	23/170
Meade et al, 1992, UK^a	WFN	75	Ischemic heart disease	No	28	Yes	244/917	324/911
Blackshear et al, 1996, US	WFN	325	Atrial fibrillation	NR	13	No	15/523	18/521
Meschengieser et al, 1997, Argentina	WFN	100	Valve replacement	No	47	No	52/245	41/258
The Medical Research Council’s General Practise Research Framework, 1998, UK^a	WFN	75	Ischemic heart disease	Yes	60	Yes	558/1,268	713/1,277
Gullov et al, 1999, Denmark^a	WFN	300	Atrial fibrillation	Yes	40	No	24/167	29/171
Laffort et al, 2000, France	WFN	200	Valve replacement	Yes	63	No	30/120	46/109
Casais et al, 2002, Argentina	WFN	100	Valve replacement	No	48	No	6/64	11/57
Hurlen et al, 2002, Norway^a	WFN	75	Myocardial infarction	Yes	48	No	136/1,216	161/1,206
Van Es et al, 2002, Netherlands^a	WFN	80	Myocardial infarction	Yes	60	No	29/325	57/332
Pengo et al, 2007, Italy	WFN	100	Valve replacement	Yes	18	No	2/104	4/94
Hart et al, 2011, US	WFN	325	Atrial fibrillation	Yes	48	No	10/509	13/508
Dong et al, 2011, China	WFN	75-100	Valve replacement	No	35	No	28/748	16/748
Wang et al, 2014, China	WFN	75-100	Valve replacement	No	35	No	20/506	18/510
Eikelboom et al, 2017, 33 countries^a	RIV	100	Coronary heart disease	Yes	23	Yes	996/9,117	1,126/9,152

Patients with bleeding events, No./Total

Study authors, year published, country

OAC

Aspirin daily
dose, mg

Indication
for OAC

Mean age
>60 y

Study duration,
mo

Blinding

OAC alone

OAC plus
aspirin

Chesebro et al, 1983, US

WFN

500

Valve replacement

9/183

23/170

Meade et al, 1992, UK^a

WFN

Ischemic heart disease

Yes

244/917

324/911

Blackshear et al, 1996, US

WFN

325

Atrial fibrillation

15/523

18/521

Meschengieser et al, 1997, Argentina

WFN

100

Valve replacement

52/245

41/258

The Medical Research Council’s General Practise Research Framework, 1998, UK^a

WFN

Ischemic heart disease

Yes

558/1,268

713/1,277

Gullov et al, 1999, Denmark^a

WFN

300

Atrial fibrillation

Yes

24/167

29/171

Laffort et al, 2000, France

WFN

200

Valve replacement

Yes

30/120

46/109

Casais et al, 2002, Argentina

WFN

100

Valve replacement

6/64

11/57

Hurlen et al, 2002, Norway^a

WFN

Myocardial infarction

Yes

136/1,216

161/1,206

Van Es et al, 2002, Netherlands^a

WFN

Myocardial infarction

Yes

29/325

57/332

Pengo et al, 2007, Italy

WFN

100

Valve replacement

Yes

2/104

4/94

Hart et al, 2011, US

WFN

325

Atrial fibrillation

Yes

10/509

13/508

Dong et al, 2011, China

WFN

75-100

Valve replacement

28/748

16/748

Wang et al, 2014, China

WFN

75-100

Valve replacement

20/506

18/510

Eikelboom et al, 2017, 33 countries^a

RIV

100

Coronary heart disease

Yes

996/9,117

1,126/9,152

							Patients with bleeding events, No./Total
Chesebro et al, 1983, US	WFN	500	Valve replacement	NR	28	No	9/183	23/170
Meade et al, 1992, UK^a	WFN	75	Ischemic heart disease	No	28	Yes	244/917	324/911
Blackshear et al, 1996, US	WFN	325	Atrial fibrillation	NR	13	No	15/523	18/521
Meschengieser et al, 1997, Argentina	WFN	100	Valve replacement	No	47	No	52/245	41/258
The Medical Research Council’s General Practise Research Framework, 1998, UK^a	WFN	75	Ischemic heart disease	Yes	60	Yes	558/1,268	713/1,277
Gullov et al, 1999, Denmark^a	WFN	300	Atrial fibrillation	Yes	40	No	24/167	29/171
Laffort et al, 2000, France	WFN	200	Valve replacement	Yes	63	No	30/120	46/109
Casais et al, 2002, Argentina	WFN	100	Valve replacement	No	48	No	6/64	11/57
Hurlen et al, 2002, Norway^a	WFN	75	Myocardial infarction	Yes	48	No	136/1,216	161/1,206
Van Es et al, 2002, Netherlands^a	WFN	80	Myocardial infarction	Yes	60	No	29/325	57/332
Pengo et al, 2007, Italy	WFN	100	Valve replacement	Yes	18	No	2/104	4/94
Hart et al, 2011, US	WFN	325	Atrial fibrillation	Yes	48	No	10/509	13/508
Dong et al, 2011, China	WFN	75-100	Valve replacement	No	35	No	28/748	16/748
Wang et al, 2014, China	WFN	75-100	Valve replacement	No	35	No	20/506	18/510
Eikelboom et al, 2017, 33 countries^a	RIV	100	Coronary heart disease	Yes	23	Yes	996/9,117	1,126/9,152

Table 1.

Open in new tab

Attributes of Randomized Controlled Trials for OAC Plus Aspirin vs OAC Alone^{16,48,49,51,53-55,57,59,61,63,66-69}

							Patients with bleeding events, No./Total
Study authors, year published, country	OAC	Aspirin daily dose, mg	Indication for OAC	Mean age >60 y	Study duration, mo	Blinding	OAC alone	OAC plus aspirin
Chesebro et al, 1983, US	WFN	500	Valve replacement	NR	28	No	9/183	23/170
Meade et al, 1992, UK^a	WFN	75	Ischemic heart disease	No	28	Yes	244/917	324/911
Blackshear et al, 1996, US	WFN	325	Atrial fibrillation	NR	13	No	15/523	18/521
Meschengieser et al, 1997, Argentina	WFN	100	Valve replacement	No	47	No	52/245	41/258
The Medical Research Council’s General Practise Research Framework, 1998, UK^a	WFN	75	Ischemic heart disease	Yes	60	Yes	558/1,268	713/1,277
Gullov et al, 1999, Denmark^a	WFN	300	Atrial fibrillation	Yes	40	No	24/167	29/171
Laffort et al, 2000, France	WFN	200	Valve replacement	Yes	63	No	30/120	46/109
Casais et al, 2002, Argentina	WFN	100	Valve replacement	No	48	No	6/64	11/57
Hurlen et al, 2002, Norway^a	WFN	75	Myocardial infarction	Yes	48	No	136/1,216	161/1,206
Van Es et al, 2002, Netherlands^a	WFN	80	Myocardial infarction	Yes	60	No	29/325	57/332
Pengo et al, 2007, Italy	WFN	100	Valve replacement	Yes	18	No	2/104	4/94
Hart et al, 2011, US	WFN	325	Atrial fibrillation	Yes	48	No	10/509	13/508
Dong et al, 2011, China	WFN	75-100	Valve replacement	No	35	No	28/748	16/748
Wang et al, 2014, China	WFN	75-100	Valve replacement	No	35	No	20/506	18/510
Eikelboom et al, 2017, 33 countries^a	RIV	100	Coronary heart disease	Yes	23	Yes	996/9,117	1,126/9,152

							Patients with bleeding events, No./Total
Study authors, year published, country	OAC	Aspirin daily dose, mg	Indication for OAC	Mean age >60 y	Study duration, mo	Blinding	OAC alone	OAC plus aspirin
Chesebro et al, 1983, US	WFN	500	Valve replacement	NR	28	No	9/183	23/170
Meade et al, 1992, UK^a	WFN	75	Ischemic heart disease	No	28	Yes	244/917	324/911
Blackshear et al, 1996, US	WFN	325	Atrial fibrillation	NR	13	No	15/523	18/521
Meschengieser et al, 1997, Argentina	WFN	100	Valve replacement	No	47	No	52/245	41/258
The Medical Research Council’s General Practise Research Framework, 1998, UK^a	WFN	75	Ischemic heart disease	Yes	60	Yes	558/1,268	713/1,277
Gullov et al, 1999, Denmark^a	WFN	300	Atrial fibrillation	Yes	40	No	24/167	29/171
Laffort et al, 2000, France	WFN	200	Valve replacement	Yes	63	No	30/120	46/109
Casais et al, 2002, Argentina	WFN	100	Valve replacement	No	48	No	6/64	11/57
Hurlen et al, 2002, Norway^a	WFN	75	Myocardial infarction	Yes	48	No	136/1,216	161/1,206
Van Es et al, 2002, Netherlands^a	WFN	80	Myocardial infarction	Yes	60	No	29/325	57/332
Pengo et al, 2007, Italy	WFN	100	Valve replacement	Yes	18	No	2/104	4/94
Hart et al, 2011, US	WFN	325	Atrial fibrillation	Yes	48	No	10/509	13/508
Dong et al, 2011, China	WFN	75-100	Valve replacement	No	35	No	28/748	16/748
Wang et al, 2014, China	WFN	75-100	Valve replacement	No	35	No	20/506	18/510
Eikelboom et al, 2017, 33 countries^a	RIV	100	Coronary heart disease	Yes	23	Yes	996/9,117	1,126/9,152

Abbreviations: NR, not reported; OAC, oral anticoagulant; RIV, rivaroxaban; WFN, warfarin.

^aStudy had 3 arms: aspirin alone, OAC alone, and OAC plus aspirin.

This Feature Is Available To Subscribers Only